|Dr. Herriot Tabuteau M.D.||Founder, Chairman, CEO & Pres||1.02M||N/A||1968|
|Mr. Nick Pizzie CPA, M.B.A.||Chief Financial Officer||570k||N/A||1975|
|Mr. Mark L. Jacobson||COO & Sec.||570k||N/A||1983|
|Dr. Cedric O'Gorman M.B.A., M.D., MBA||Sr. VP of Medical Affairs||N/A||N/A||1975|
|Dr. Amanda Jones Pharm.D.||Sr. VP of Clinical Devel.||N/A||N/A||1984|
|Ms. Lori Englebert M.B.A.||Sr. VP of Commercial & Bus. Devel.||N/A||N/A||1978|
|Mr. Kevin Laliberte Pharm.D.||Exec. VP of Product Strategy||N/A||N/A||1978|
|Joseph Debrah-Afful CPA, M.B.A.||Director of Fin.||N/A||N/A||N/A|
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Axsome Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.